AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Aurinia Pharmaceuticals Inc
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S68013
16.86▼ 0.47 (-2.71%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
17.33
Day's Range
16.81 – 17.31
52-Week Range
11.48 – 19.25
Volume
625.0K
Avg Volume
821.7K
Share Statistics
Shares Outstanding
Employees
128
Exchange
XNAS
Listed
2009-10-21
Share count as of August 5, 2026

Aurinia Pharmaceuticals Inc (AUPH) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Aurinia Pharmaceuticals Inc (AUPH)
What is Aurinia Pharmaceuticals Inc's Market Cap?
Aurinia Pharmaceuticals Inc's Market Cap is $2.2B, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Enterprise Value?
Aurinia Pharmaceuticals Inc's Enterprise Value is $2.1B, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Trailing P/E?
Aurinia Pharmaceuticals Inc's Trailing P/E is 7.1×, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Price / Sales?
Aurinia Pharmaceuticals Inc's Price / Sales is 7.2×, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's EV / Revenue?
Aurinia Pharmaceuticals Inc's EV / Revenue is 6.8×, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's EV / EBITDA?
Aurinia Pharmaceuticals Inc's EV / EBITDA is 12.5×, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Revenue (TTM)?
Aurinia Pharmaceuticals Inc's Revenue (TTM) is $311.5M, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Net Income (TTM)?
Aurinia Pharmaceuticals Inc's Net Income (TTM) is $314.1M, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's EBITDA?
Aurinia Pharmaceuticals Inc's EBITDA is $170.1M, based on as-reported figures from SEC (XBRL) filings.
What is Aurinia Pharmaceuticals Inc's Diluted EPS (TTM)?
Aurinia Pharmaceuticals Inc's Diluted EPS (TTM) is 2.36, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AUPHAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
Total revenue
YoY growth+18.9%+24.4%+28.8%+8.4%
Operating expenses
Cost of revenue
Selling, general and administrative
Research and development
Restructuring
Other (income) expense, net
Total operating expenses
% of revenue44.3%46.7%56.9%59.5%
Income from operations
% of revenue55.7%53.3%43.1%40.5%
Interest income
Interest expense
Net income before income taxes
Net income
% of revenue45.0%44.2%273.4%42.9%
Basic (in usd per share)
Diluted (in usd per share)